Small interfering RNA (siRNA) inhibits the expression of the Her2/Neu gene, upregulates HLA class I and induces apoptosis of Her2/Neu positive tumor cell lines

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 71-77

  Choudhury, Aniruddha ^a   Charo, Jehad ^a,d   Parapuram, Sunil K ^b   Hunt, Richard C ^b   Hunt, D Margaret ^b   Seliger, Barbara ^c   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Breast cancer; Her 2 neu; Oncogene; RNAi; SiRNA

Indexed keywords

HLA ANTIGEN CLASS 1; MESSENGER RNA; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL FUNCTION; CELL SURFACE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; STOMACH CANCER; UPREGULATION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE SILENCING; GENES, ERBB-2; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 0344825125     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11497     Document Type: Article

References (34)

1. Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA 2001;7:1509-21.
2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
3. Boutla A, Delidakis C, Livadaras I, Tsagris M, Tabler M. Short 5′-phosphorylated double-stranded RNAs induce RNA interference in Drosophila. Curr Biol 2001;11:1776-80.
4. Djikeng A, Shi H, Tschudi C, Ullu E. RNA interference in Trypanosoma brucei: cloning of small interfering RNAs provides evidence for retroposon-derived 24-26-nucleotide RNAs. RNA 2001;7:1522-30.
5. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 2001;20:6877-88.
6. Akashi H, Miyagishi M, Taira K. Suppression of gene expression by RNA interference in cultured plant cells. Antisense Nucleic Acid Drug Dev 2001;11:359-67.
7. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002;8:681-6.
8. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 2002;99:8672-6.
9. Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001;2:239-45.
10. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
11. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
12. Kern JA, Robinson RA, Gazdar A, Torney L, Weiner DB. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am J Respir Cell Mol Biol 1992;6:359-63.
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
14. Williams TM, Weiner DB, Greene MI, Maguire Jr HC. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 1991;59:46-52.
15. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61:1-13.
16. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
17. Drebin JA, Link VC, Weinberg RA, Greene MI, Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986;83:9129-33.
18. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, et al. Phase II study of weekly intravenous recombinant hmanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
19. Brodowicz T, Wiltschke C, Budinsky AC, Kramer M, Steger GG, Zielinski CC. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997;73:875-9.
20. Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast Jr RC. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997;3:1629-34.
21. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-93.
22. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2061;29:E45-5.
23. Roh H, Pippin J, Drebin JA. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 2000;60:560-5.
24. Roh H, Pippin J, Boswell C, Drebin JA. Antisense ligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res 1998;77:85-90.
25. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003;13:1-7.
26. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast Jr RC. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 2000;6:260-70.
27. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
28. Kleinberger-Doron N, Shelah N, Capone R, Gazit A, Levitzki A. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res 1998;241:340-51.
29. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12:S35-41.
30. Kumar R, Shepard HM, Mendelsohn J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 1991;11:979-86.
31. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
32. Seliger B, Harders C, Lohmann S, Momburg F, Urlinger S, Tampe R, Huber C. Down-regulation of the HLA class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol 1998;28:122-33.
33. Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van't Veer LJ, Kruse-Wolters KM. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol 1991;2:73-83.
34. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.